Want to see CIRC full AI Analyst Report?
Top Page
Circle8 Group
(NASDAQ:CIRC)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.70
▼(-12.03% Downside)
Action:Reiterated
Date:07/10/26
The score is primarily weighed down by weak financial performance—ongoing losses, negative free cash flow, and high leverage relative to equity—despite strong recent revenue growth. Technicals also reflect a broader downtrend (below key moving averages with negative MACD), with only a modest offset from near-term oversold readings. Valuation provides limited support because the negative P/E reflects unprofitable operations and no dividend yield is available.
Positive Factors
Revenue Growth
TTM revenue growth of +33.7% reflects durable demand expansion and a growing top line, which can enable scalable fixed-cost absorption and improved operating leverage. Sustained top-line momentum increases the probability the company can convert growth into profitable scale over time.
Negative Factors
Elevated Leverage
High debt relative to a modest equity base materially increases financial risk and reduces flexibility. Elevated leverage raises refinancing and interest burdens, constrains capital allocation, and heightens solvency sensitivity if cash generation and margins do not improve sustainably.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
TTM revenue growth of +33.7% reflects durable demand expansion and a growing top line, which can enable scalable fixed-cost absorption and improved operating leverage. Sustained top-line momentum increases the probability the company can convert growth into profitable scale over time.
Read all positive factors
Circle8 Group (CIRC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$64.50M
Dividend YieldN/A
Average Volume (3M)364.23K
Price to Earnings (P/E)―
Beta (1Y)-0.65
Revenue Growth27.45%
EPS Growth82.80%
CountryUS
Employees300
SectorIndustrials
Sector Strength72
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)-1.32
Shares Outstanding89,963,170
10 Day Avg. Volume70,257
30 Day Avg. Volume364,234
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-2.27
Price to Sales (P/S)0.17
P/FCF Ratio-16.34
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.61
Revenue Forecast (FY)$481.08M
Circle8 Group Business Overview & Revenue Model
Company Description
Circle8 Group is a global technology and workforce solutions company serving enterprise, government, and multinational organizations across North America and Europe. The company provides Technology Consulting, Technology Solutions, Managed Service...
How the Company Makes Money
null...
Circle8 Group Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
18
Very Negative
Cash Flow
20
Very Negative
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Circle8 Group Risk Analysis
Circle8 Group disclosed 48 risk factors in its most recent earnings report. Circle8 Group reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Circle8 Group Peers Comparison
UnderperformOutperform
Sector (63)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
56 Neutral | $319.55M | -4.07 | -46.74% | ― | 167.42% | -22.94% | |
54 Neutral | $726.25M | -9.29 | -55.89% | ― | -52.94% | 59.88% | |
50 Neutral | $109.44M | -5.03 | -113.53% | ― | 20.55% | -4.63% | |
47 Neutral | $137.78M | -3.67 | -164.68% | ― | 69.52% | 58.15% | |
44 Neutral | $64.50M | -0.68 | 274.33% | ― | 27.45% | 82.80% | |
42 Neutral | $21.47M | -0.62 | 402.97% | ― | 17.42% | 42.75% |
* Industrials Sector Average
CIRC
Circle8 Group
0.72
-0.86
-54.62%
ACRS
Aclaris Therapeutics
5.20
3.64
233.33%
MDXH
MDxHealth
0.42
-2.05
-83.08%
STIM
Neuronetics
1.98
-2.68
-57.51%
XGN
Exagen
4.53
-4.32
-48.81%
PRE
Prenetics Group
18.64
10.82
138.36%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.